Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | FDPS | P14324 | 4/20 | 0.36 |
| ▸ | LAP3 | P28838 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 3/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propylene Glycol SCHEMBL315221 | 0.94 | TDP1 (0.67) | TDP1TSHRFDPSLAP3ALDH1A1 | |
| Propylene Glycol SCHEMBL22285873 | 0.94 | TDP1 (0.67) | TDP1TSHRFDPSLAP3ALDH1A1 | |
| Propylene Glycol SCHEMBL6852797 | 0.94 | TDP1 (0.67) | TDP1TSHRFDPSLAP3ALDH1A1 | |
| Propylene Glycol SCHEMBL27549086 | 0.91 | TDP1 (0.62) | TDP1TSHRFDPSLAP3ALDH1A1 | |
| Propylene Glycol SCHEMBL7862899 | 0.91 | TDP1 (0.62) | TDP1TSHRFDPSLAP3ALDH1A1 | |
| Propylene Glycol SCHEMBL29186483 | 0.91 | TDP1 (0.62) | TDP1TSHRFDPSLAP3ALDH1A1 | |
| Propylene Glycol SCHEMBL29249405 | 0.91 | TDP1 (0.62) | TDP1TSHRFDPSLAP3ALDH1A1 | |
| Propylene Glycol SCHEMBL28091290 | 0.91 | TDP1 (0.62) | TDP1TSHRFDPSLAP3ALDH1A1 | |
| Propylene Glycol SCHEMBL28569058 | 0.85 | TDP1 (0.62) | TDP1TSHRFDPSLAP3ALDH1A1 | |
| Propylene Glycol SCHEMBL5486872 | 0.85 | TDP1 (0.62) | TDP1TSHRFDPSLAP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE40387-E1 | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | claimed |
| US-6936628-B2 | Orally administering one or more pharmaceutically acceptable acid neutralizing buffers with epothiolones (simultaneously, before or after) to increase the vioavailability of epothiolones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | claimed |
| US-20030220378-A1 | Oral administration of epothilones | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-27 | — | — | US | claimed |
| EP-1361877-A1 | PHARMACEUTICAL DOSAGE FORMS OF EPOTHILONES FOR ORAL ADMINISTRATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-19 | — | — | EP | claimed |
| US-6576651-B2 | Such as (1S-(1R*,3R*(E),7R*,10S*,11R*,16S*))-7,11-dihydroxy 8,8,10,12,16-pentamethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl) ethenyl-17-oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione; bioavailability | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-10 | — | — | US | claimed |
| US-20020177615-A1 | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones | R-PHARM US OPERATING LLC | 2002-11-28 | — | — | US | claimed |
| WO-2002058701-A1 | PHARMACEUTICAL DOSAGE FORMS OF EPOTHILONES FOR ORAL ADMINISTRATION | BRISTOL-MYERS SQUIBB CO. (US) | 2002-08-01 | — | — | WO | claimed |
| EP-1938821-B1 | Dosage forms of an epothilone analogue for the treatment of cancer | BRISTOL MYERS SQUIBB CO (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-1938821-A2 | Methods of administering epothilone analogs for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-02 | — | — | EP | disclosed |
| US-RE40387-E1 | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| EP-1353668-B1 | PROCESSES FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS CONTAINING EPOTHILONE ANALOGUES FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7053069-B2 | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-6936628-B2 | Orally administering one or more pharmaceutically acceptable acid neutralizing buffers with epothiolones (simultaneously, before or after) to increase the vioavailability of epothiolones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1361877-A1 | PHARMACEUTICAL DOSAGE FORMS OF EPOTHILONES FOR ORAL ADMINISTRATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2003084536-A1 | ORAL ADMINISTRATION OF EPOTHILONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
| US-6576651-B2 | Such as (1S-(1R*,3R*(E),7R*,10S*,11R*,16S*))-7,11-dihydroxy 8,8,10,12,16-pentamethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl) ethenyl-17-oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione; bioavailability | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-10 | — | — | US | disclosed |
| US-20020177615-A1 | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones | R-PHARM US OPERATING LLC | 2002-11-28 | — | — | US | disclosed |
| US-20020169190-A1 | Dosing schedule of antitumor agents | R-PHARM US OPERATING LLC | 2002-11-14 | — | — | US | disclosed |
| WO-2002058699-A1 | PHARMACEUTICAL FORMS OF EPOTHILONES FOR ORAL ADMINISTRATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058701-A1 | PHARMACEUTICAL DOSAGE FORMS OF EPOTHILONES FOR ORAL ADMINISTRATION | BRISTOL-MYERS SQUIBB CO. (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220378-A1 | Oral administration of epothilones | EPOR, DHPS, SQLE | TDP1 4123/4885TSHR 2204/4885FDPS 141/4885 |
| US-20020177615-A1 | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones | EPOR, DHPS, SQLE | TDP1 3910/4885TSHR 2643/4885FDPS 87/4885 |
| US-20020169190-A1 | Dosing schedule of antitumor agents | TTPA, SORD, LPXN | TDP1 2276/4885TSHR 2721/4885FDPS 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.